No CrossRef data available.
Article contents
OBSTETRIC ANTIPHOSPHOLIPID SYNDROME - A REVIEW
Published online by Cambridge University Press: 03 November 2011
Extract
The Antiphospholipid syndrome (APS) is one of the current hot topics embracing rheumatology and obstetrics.
The first clinical description of APS was in 1983. Venous or arterial thrombosis, abortion and cerebral manifestations along with circulating antibodies were the first described hallmarks of the syndrome. In the following years other clinical features, which include pregnancy complications, such as recurrent miscarriages (RM), pre-eclampsia or severe placental insufficiency were described.
- Type
- Review Article
- Information
- Copyright
- Copyright © Cambridge University Press 2011
References
REFERENCES
1Harris, EN, Gharavi, AE, Boey, ML, Patel, BM, Mackworth-Young, CG, Loizou, S, et al. Anticardiolipin antibodies: detection by radioimmuneoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 26: 1211–214.CrossRefGoogle Scholar
2Miyakis, S, Lockshin, MD, Atsumi, T, Branch, DW, Brey, RL, Cervera, R, et al. International consensus statement on an update to the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295–306.CrossRefGoogle Scholar
3Cervera, R, Abarca-Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, AO et al. ; Lessons from the ‘Euro-Lupus Cohort’. Ann Med Interne (Paris) 2002; 153: 530–36.Google ScholarPubMed
4Steegers, EA, von Dadelszen, P, Duvekot, JJ, Pijnenborg, R. Pre-eclampsia. Lancet 2010; 376: 631–44.Google Scholar
5Rai, RS, Clifford, K, Cohen, H, Regan, L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodes. Hum Reprod 1995; 10: 3301–304.CrossRefGoogle Scholar
6Branch, DW, Khamashta, MA. Antiphospholipid syndrome: Obstetric diagnosis, management and controversies. Obstet Gynecol 2003; 101:1333–44.Google ScholarPubMed
7Yang, YH, Chien, D, Wu, M, FitzGerald, J, Grossman, JM, Hahn, BH et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphophospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009; 182: 1674–680.CrossRefGoogle Scholar
8Hwang, KK, Yang, CD, Yan, W, Grossman, JM, Hahn, BH, Chen, PP. A thrombin-cross-reactive aticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48: 1622–630.CrossRefGoogle ScholarPubMed
9Yang, CD, Hwang, KK, Yan, W, Gallagher, K, FitzGerald, J, Grossman, JM et al. Identification if anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765–773.CrossRefGoogle ScholarPubMed
10Yang, YH, Hwang, KK, FitzGerald, J, Grossman, JM, Taylor, M, Hahn, BH et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006; 177: 8219–225.CrossRefGoogle ScholarPubMed
11Galli, M, Luciani, D, Bertolini, G, Barbui, T. Anti-beta 2-glycoprotein I, antithrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717–23.CrossRefGoogle Scholar
12Matsubayashi, H, Arai, T, Izumi, S, Sugi, T, McIntyre, JA, Makino, T. Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil Steril 2001; 76: 694–99.Google Scholar
13Rand, JH, Wu, XX, Quinn, AS, Taatjes, DJ. The annexin a5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Review Lupus 2010; 19: 460–69.Google Scholar
14Pierangeli, SS, Chen, PP, Raschi, E, Scurati, S, Grossi, C, Borghi, MO et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008; 34: 236–50.Google Scholar
15López-Pedrera, C, Buendía, P, Cuadrado, MJ, Siendones, E, Aguirre, MA, Barbarroja, N et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301–11.CrossRefGoogle ScholarPubMed
16Holers, VM, Girardi, G, Mo, L, Guthridge, JM, Molina, H, Pierangeli, SS et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211–20.CrossRefGoogle ScholarPubMed
17Oberkersch, R, Attorresi, AI, Calabrese, GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010; 125: 240–45.CrossRefGoogle ScholarPubMed
18Yang, L, Sun, MF, Gailani, D, Rezaie, AR. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry 2009; 48: 1517–524.CrossRefGoogle ScholarPubMed
19Girardi, G, Redecha, P, Salmon, JE. Heparin prevents aPL induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–26.CrossRefGoogle ScholarPubMed
20Salmon, JE, de Groot, PG. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17: 405–11.CrossRefGoogle ScholarPubMed
21Scoble, T, Wijetilleka, S, Khamashta, MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011; May 1. [Epub ahead of print] doi:10.1016/j.autrev.2011.04.030Google Scholar
22Asherson, RA. The primary, secondary, catastrophic and seronegative variance of the antiphospholipid syndrome; a personal history long in the making. Semin Thromb Hemost 2008; 34: 227–235.CrossRefGoogle Scholar
23Cervera, R, Khamashta, MA, Font, J, Sebastiani, GD, Gil, A, Lavilla, P et al. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1.000 patients. Arthritis Rheum 2002; 46: 1019–27.Google Scholar
24Sanna, G, Bertolaccini, ML, Cuadrado, MJ, Khamashta, MA, Hughes, GR. Central nervous system involvment in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003; 42: 200–213.CrossRefGoogle ScholarPubMed
25Cervera, R, Boffa, MC, Khamashta, MA, Hughes, GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009; 18: 889–893.CrossRefGoogle ScholarPubMed
26Finazzi, G. The Italian Registry of Antiphospholipid Antibodies. Haematologica 1997; 82: 101–105.Google ScholarPubMed
27Francès, C, Niang, S, Laffitte, E, Pelletier, F, Costedoat, N, Piette, JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785–793.CrossRefGoogle ScholarPubMed
28Nayak, AK, Komatireddy, G. Cardiac manifestations of the antiphospholipid antibody syndrome: a review. Mo Med 2002; 99: 171–78.Google Scholar
29Vaarala, O, Puurunen, M, Mänttäri, M, Manninen, V, Aho, K, Palosuo, T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456–59.Google ScholarPubMed
30Urbanus, RT, Siegerink, B, Roest, M, Rosendaal, FR, de Groot, PG, Algra, A. Antiphospholipid antibodies and risk of myocardial infarction and ischemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998–1005.CrossRefGoogle Scholar
31Erkan, D, Asherson, RA, Espinosa, G, Cervera, R, Font, J, Piette, JC et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rhem Dis 2003; 62: 530–33.CrossRefGoogle ScholarPubMed
32Asherson, RA, Cervera, R, de Groot, PG, Erkan, D, Boffa, MC, Piette, JC et al. ; Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530–34.CrossRefGoogle ScholarPubMed
33Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498–509.Google Scholar
34Empson, M, Lassere, M, Craig, J, Scott, J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or Lupus anticoagulant. Cochrane Database Syst Rev 2005; 18: CD002859.Google Scholar
35Pattison, NS, Chamley, LW, McKay, EJ, Liggins, GC, Butler, WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909–13.Google Scholar
36Yasuda, M, Takakuwa, K, Tokunaga, A, Tanaka, K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995; 86: 555–59.CrossRefGoogle ScholarPubMed
37Lynch, A, Marlar, R, Murphy, J, Davila, G, Santos, M, Rutledge, J et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Inten Med 1994; 120: 470–75.CrossRefGoogle ScholarPubMed
38Katano, K, Aoki, A, Sasa, H, Ogasawara, M, Matsuura, E, Yagami, Y. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509–12.CrossRefGoogle ScholarPubMed
39Faden, D, Tincani, A, Tanzi, P, Spatola, L, Lojacono, A, Tarantini, M et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 1997; 73: 37–42.Google Scholar
40Yamada, H, Atsumi, T, Amengual, O, Koike, T, Furuta, I, Ohta, K et al. Glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. J Reprod Immunol 2010; 84: 95–99.CrossRefGoogle ScholarPubMed
41Regan, L, Braude, PR, Trembath, PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989; 299: 541–45.CrossRefGoogle ScholarPubMed
42Stirrat, GM.Recurrent miscarriage I: definition and epidemiology. Lancet 1990; 336: 673–75.CrossRefGoogle Scholar
43RCOG. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. Green-top guidelines No. 17, 2011: 1–18. http://www.rcog.org.uk/files/rcog-corp/GTG17recurrentmiscarriage.pdfGoogle Scholar
44Petri, M, Golbus, M, Anderson, R, Whiting-O'Keefe, Q, Corash, L, Hellmann, D. Antinuclearantibody, lupus anticoagulant, and anticardiolipin antibody in women with idio- pathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987; 30: 601–606.CrossRefGoogle Scholar
45Clifford, K, Rai, R, Watson, H, Regan, L. Pregnancy: an informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 1994; 9: 1328–332.Google Scholar
46Yetman, DL, Kutteh, WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66: 540–46.Google Scholar
47Reznikoff-Etievant, MF, Cayol, V, Zou, GM, Abuaf, N, Robert, A, Johanet, C et al. Habitual abor- tions in 678 healthy patients: investigation and prevention. Hum Reprod 1999; 14: 2106–109.Google Scholar
48Rai, RS, Regan, L, Clifford, K, Pickering, W, Dave, M, Mackie, I et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriages: results of a comprehensive screening approach. Hum Reprod 1995; 10: 2001–2005.Google Scholar
49Nybo Andersen, AM, Wohlfahrt, J, Christens, P, Olsen, J, Melbye, M. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320: 1708–712.Google Scholar
50Lockwood, CJ, Romero, R, Feinberg, RF, Clyne, LP, Coster, B, Hobbins, JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369–373.Google Scholar
51Cervera, R, Khamashta, MA, Shoenfeld, Y, Camps, MT, Jacobsen, S, Kiss, E et al. Morbidity and mortality in the antiphospholipid syndrome during a five year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428–432.CrossRefGoogle Scholar
52Empson, M, Lassere, M, Craig, JC, Scott, JR. Recurrent pregnancy loss with antiphospholipid antibody; a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135–44.Google Scholar
53Farquharson, RG, Quenby, S, Greaves, M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408–13.Google Scholar
54Kutteh, WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584–589.Google Scholar
55Rai, R, Cohen, H, Dave, M, Regan, L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphosphilipid antibodies). BMJ 1997; 314: 253–57.Google Scholar
56Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791–798.Google Scholar
57Carmona, F, Font, J, Azulay, M, Creus, M, Fábregues, F, Cervera, R. Risk factors associated with fetal loss in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46: 274–79.Google Scholar
58Silver, RK, MacGregor, SN, Sholl, JS, Hobart, JM, Neerhof, MG, Ragin, A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411–417.Google Scholar
59Di Simone, N, Ferrazzani, S, Castellani, R, De Carolis, S, Mancuso, S, Caruso, A. Heparin and low dose aspirin restore placental chorionic gonadotropin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997; 12: 2061–65.Google Scholar
60Di Simone, N, Caliandro, D, Castellani, R, Ferrazzani, S, De Carolis, S, Caruso, A. Low-molecular weight heparin restores in-vitro trophoblasts invasiveness and differentiation in presence of immunoglobin G fractiones obtained from patients with antiphospholipid syndrome. Hum Reprod 1999; 14: 489–95.Google Scholar
61Di Simone, N, Meroni, PL, D'Asta, M, Di Nicuolo, F, D'Alessio, MC, Caruso, A. Pathogenic role of anti-beta2-glycoproteinI antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007; 13: 189–96.Google Scholar
62Bates, SM, Greer, IA, Pabinger, I, Sofaer, S, Hirsh, J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physcians Evidence-Based Clinical Practice guidelines. (8th edn.) Chest 2008; 133: 844S–86S.CrossRefGoogle Scholar
63Branch, W. Obstetric task force. Report of the Obestetric Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus; 2010; 20: 158–64.CrossRefGoogle Scholar
65Oshiro, BT, Silver, RM, Scott, JR, Yu, H, Branch, DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489–93.CrossRefGoogle ScholarPubMed
66Opatrny, L, David, M, Kahn, SR, Shrier, I, Rey, E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33: 2214–221.Google Scholar
67Rey, E, Garneau, P, David, M, Gauthier, R, Leduc, L, Michon, N, Morin, F et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58–64CrossRefGoogle ScholarPubMed
68Meis, PJ, Goldenberg, RL, Mercer, BM, Iams, JD, Moawad, AH, Miodovnik, M et al. for the Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. The preterm prediction study: risk factors for indicated preterm births. Am J Obstet Gynecol 1998; 178: 562–67.Google Scholar
69Tuffnell, DJ, Jankowicz, D, Lindow, SW, Lyons, G, Mason, GC, Russell, IF et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG 2005; 112: 875–80CrossRefGoogle ScholarPubMed
70Clark, EA, Silver, RM, Branch, DW. Do antiphospholipid antibodies cause pre-eclampsia and HELLP syndrome? Curr Rheumatol Rep 2007; 9: 219–25.Google Scholar
71Lynch, A, Marlar, R, Murphy, J, Davila, G, Santos, M, Rutledge, J et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med 1994; 120: 470–75.Google Scholar
72Katano, K, Aoki, A, Sasa, H, Ogasawara, M, Matsuura, E, Yagami, Y. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509–12.Google Scholar
73Faden, D, Tincani, A, Tanzi, P, Spatola, L, Lojacono, A, Tarantini, M, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 1997; 73: 37–42.CrossRefGoogle Scholar
74Yamada, H, Atsumi, T, Amengual, O, Koike, T, Furuta, I, Ohta, K, et al. Anti-beta2 glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. J Reprod Immunol 2010; 84: 95–99.Google Scholar
75do Prado, AD, Piovesan, DM, Staub, HL, Horta, BL. Association of Anticardiolipin Antibodies with preeclampsia. Obstet Gynecol 2010; 116: 1433–443.Google Scholar
76Yamada, H, Atsumi, T, Kobashi, G, Ota, C, Kato Emi, H, Tsuruga, N et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79: 188–95.CrossRefGoogle ScholarPubMed
77Stone, S, Pijnenborg, R, Vercruysse, L, Poston, R, Khamashta, MA, Hunt, BJ et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta 2006; 27: 457–67.CrossRefGoogle ScholarPubMed
78Clark, EA, Silver, RM, Branch, DW. Do antiphospholipid antibodies cause pre-eclampsia and HELLP syndrome? Curr Rheumatol Rep 2007; 9: 219–25.Google Scholar
79Ruffatti, A, Tonello, M, Cavazzana, A, Bagatella, P, Pengo, V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 2009; 123: 482–87.Google Scholar
80Dreyfus, M, Hedelin, G, Kutnahorsky, R, Lehmann, M, Viville, B, Langer, B, et al. Antiphospholipid antibodies and pre-eclampsia: A case-control study. Obstet Gynecol 2001; 97: 29–34.Google ScholarPubMed
81Branch, DW, Porter, TF, Rittenhouse, L, Caritis, S, Sibai, B, Hogg, B, et al. Antiphospholipid antibodies in women at risk for pre-eclampsia. Am J Obstet Gynecol 2001; 184: 825–832.Google Scholar
82Lee, RM, Brown, MA, Branch, DW, Ward, K, Silver, RM. Anticardiolipin and antibeta2-glycoprotein-I antibodies in pre-eclampsia. Obstet Gynecol 2003; 102: 294–300.Google Scholar
83Askie, LM, Duley, L, Henderson-Smart, DJ, Stewart, LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia, a metaanalysis of individual patient data. Lancet 2007; 369: 1791–98.CrossRefGoogle ScholarPubMed
84Le Thi Thuong, D, Tieulié, N, Costedoat, N, Andreu, MR, Wechsler, B, Vauthier-Brouzes, D, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005; 64: 273–78.CrossRefGoogle ScholarPubMed
85Girón-González, JA, García del Río, E, Rodríguez, C, Rodríguez-Martorell, J, Serrano, A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospectiv analysis of 404 individuals. J Rheumatol 2004; 31: 1560–567.Google Scholar
86Ruffatti, A, Del Ross, T, Ciprian, M, Bertero, MT, Salvatore, S, Scarpato, S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70: 1083–86.Google Scholar
87Erkan, D, Merrill, JT, Yazici, Y, Sammaritano, L, Buyon, JP, Lockshin, MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466–467.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
88Finazzi, G, Brancaccio, V, Moia, M, Ciaverella, N, Mazzucconi, MG, Schinco, PC et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996; 100: 530–36.CrossRefGoogle ScholarPubMed
89Quenby, S, Farquharson, RG, Dawood, F, Hughes, AM, Topping, J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod 2005; 20: 1729–732.Google Scholar
90Lefèvre, G, Lambert, M, Bacri, JL, Dubucquoi, S, Quemeneur, T, Caron, C, et al. Thrombotic events during long term follow-up of obstetrical antiphospholipid syndrome patients. Lupus 2011; 20: 861–65.CrossRefGoogle ScholarPubMed
91Erkan, D, Yazici, Y, Peterson, MG, Sammaritano, L, Lockshin, MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924–29.CrossRefGoogle ScholarPubMed
92Tarr, T, Lakos, G, Bhattoa, HP, Shoenfeld, Y, Szegedi, G, Kiss, E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39–45.Google Scholar
93Hereng, T, Lambert, M, Hachulla, E, Samor, M, Dubucquoi, S, Caron, C et al. Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008; 17: 11–15.Google Scholar
94Wahl, DG, Bounameaux, H, de Moerloose, P, Sarasin, FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arch Intern Med 2000; 160: 2042–48.CrossRefGoogle ScholarPubMed
95Erkan, D, Harrison, MJ, Levy, R, Peterson, M, Petri, M, Sammaritano, L et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382–391.CrossRefGoogle ScholarPubMed
96Chan, AT, Manson, JE, Feskanich, D, Stampfer, MJ, Colditz, GA, Fuchs, CS. Long term aspirin use and mortality in women. Arch Int Med 2007; 167: 562–72.CrossRefGoogle ScholarPubMed
97Tektonidou, MG, Laskari, K, Panagiotakos, DB, Moutsopoulos, HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.Google Scholar
98Galli, M, Luciani, D, Bertolini, G, Barbui, T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–832.CrossRefGoogle ScholarPubMed
99Martinez-Berriotxoa, A, Ruiz-Irastorza, G, Egurbide, MV, Garmendia, M, Gabriel Erdozain, J, Villar, I, et al. Transiently positive anticardiolipin antibodies do not increase the risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007; 16: 810–16.Google Scholar
100Pengo, V, Biasiolo, A, Pegoraro, C, Cucchini, U, Noventa, F, Iliceto, S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147–152.Google Scholar
101Ruiz-Irastorza, G, Cuadrado, MJ, Ruiz-Arruza, I, Brey, R, Crowther, M, Derksen, R et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20: 206–18.Google Scholar
102RCOG. Venous thromboembolism and hormonal contraception. Green-top Guidelines No. 40, 2010: 1–13. http://www.rcog.org.uk/files/rcog-corp/GTG40VenousThromboEmbolism0910.pdfGoogle Scholar
103Østensen, M, Khamashta, M, Lockshin, M, Parke, A, Brucato, A, Carp, H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209–22.Google Scholar
104Horlocker, TT, Wedel, DJ, Rowlingson, JC, Enneking, FK, Kopp, SL, Benzon, HT, et al. American College of Chest Physicians. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64–101.Google Scholar
105Khamashta, MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol 2006; 20: 685–94.Google Scholar
106Ruiz-Irastorza, G, Khamashta, MA. Lupus and pregnancy: ten questions and some answers. Lupus 2008; 17: 416–20.Google Scholar
107RCOG. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guidelines No. 37, 2009: 1–35. http://www.rcog.org.uk/womens-health/clinical-guidance/reducing-risk-of-thrombosis-greentop37Google Scholar
108Le Thi Huong, D, Wechsler, B, Vauthier-Brouzes, D, Duhaut, P, Costedoat, N, Andreu, MR et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45: 332–38.Google Scholar
109Bramham, K, Thomas, M, Nelson-Piercy, C, Khamashta, M, Hunt, BJ. First trimester low dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011; 117: 6948–951.Google Scholar
110Rand, JH, Wu, XX, Quinn, AS, Taatjes, DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010; 19: 460–69.Google Scholar
111Pierangeli, SS, Erkan, D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010; 19: 475–85.Google Scholar
112Laskin, CA, Bombardier, C, Hannah, ME, Mandel, FP, Ritchie, JW, Farewell, V et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148–53.Google Scholar
113Salmon, JE, Girardi, G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77: 51–56.CrossRefGoogle Scholar
114Vinet, E, Pineau, C, Gordon, C, Clarke, AE, Bernatsky, S. Biologic Therapy and Pregnancy Outcomes in Women With Rheumatic Diseases. Arthritis Rheum 2009; 61: 587–92.CrossRefGoogle ScholarPubMed
115Dendrinos, S, Sakkas, E, Makrakis, E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009; 104: 223–25.Google Scholar
116Triolo, G, Ferrante, A, Ciccia, F, Accardo-Palumbo, A, Perino, A, Castelli, A et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728–31.Google Scholar
117Branch, DW, Peaceman, AM, Druzin, M, Silver, RK, El-Sayed, Y, Silver, RM et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182: 122–27.Google Scholar
118Horlocker, T, Wedel, D, Rowlingson, J, Enneking, F, American College of Chest Physicians. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64–101.Google Scholar
119Douketis, J, Berger, P, Dunn, A, Jaffer, A, Spyropoulos, A, Becker, R, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 299S–339SGoogle Scholar
120Ruiz-Irastorza, G, Khamashta, MA, Hughes, GR. Heparin and osteoporosis during pregnancy: 2002 update. Lupus 2002; 11: 680–82.Google Scholar
121Ruiz-Irastorza, G, Khamashta, MA, Nelson-Piercy, C, Hughes, GR. Lupus pregnancy: is heparin a risk factor for osteoporosis? Lupus 2001; 10: 597–600Google Scholar
122Shefras, J, Farquharson, RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171–74.Google Scholar
123Backos, M, Rai, R, Thomas, E, Murphy, M, Dore, C, Regan, L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14: 2876–880.Google Scholar
124Lefkou, E, Khamashta, M, Hampson, G, Hunt, BJ. Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: A myth or an existing entity? Lupus 2010; 19: 3–12Google Scholar
125Hofmeyr, GJ, Lawrie, TA, Atallah, AN, Duley, L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010;(8): CD001059Google Scholar
126ESPRIT Study Group, Halkes, PH, vin Gijn, J, Kappelle, LJ, Koudstaad, PJ, Algra, A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin. (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–73.Google Scholar
127ACTIVE Investigators, Connolly, SJ, Pogue, J, Hart, RG, Hohnloser, SH, Pfeffer, M, et al. Effect of clopidogrel added to aspirin in patients with artrial fibrillation. N Engl J Med 2009; 360: 2066–78.Google Scholar
128Connolly, SJ, Connolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–151.CrossRefGoogle ScholarPubMed
129Schulman, S, Kearon, C, Kakkar, AK, Mismetti, P, Schellong, S, Eriksson, H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–352.Google Scholar
130Ruiz-Irastorza, G, Ramos-Casals, M, Brito-Zeron, P, Khamashta, MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–28.Google Scholar
131Rand, JH, Wu, XX, Quinn, AS, Ashton, AW, Chen, PP, Hathcock, JJ, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292–299.Google Scholar
132Meroni, PL, Raschi, E, Testoni, C, Tincani, A, Balestrieri, G, Molteni, R, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870–878.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
133Jajoria, P, Murthy, V, Papalardo, E, Romay-Penabad, Z, Gleason, C, Pierangeli, SS. Statins for the treatment of antiphospholipid syndrome? Ann N Y Acad 2009; 1173: 736–45.Google Scholar
134Kumasawa, K, Ikawa, M, Kidoya, H, Hasuwa, H, Saito-Fujita, T, Morioka, Y et al. Pravastatin induces placental growth factor (PGF) and ameliorates pre-eclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108: 1415–415.CrossRefGoogle ScholarPubMed
135Ahmed, A, Singh, J, Khan, Y, Seshan, SV, Girardi, G. A new mouse model to explore therapies for pre-eclampsia. PLoS One 2011; 5: e13663.Google Scholar
136Youinou, P, Renaudineau, Y. The antiphospholipid syndrome as a model for B cell-induced autoimmune disease. Thromb Res 2004; 114: 363–69.Google Scholar
137Kahn, P, Ramanujam, M, Bethunaickan, R, Huang, W, Tao, H, Madaio, MP et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008; 58: 2824–34.Google Scholar
138Swadzba, J, Iwaniec, T, Musial, J. Increased level of tumor necrosis factor-aplha in patients with antiphospholipid syndrome: marker not only of inflammation but also of the thrombotic state. Rheumatol Int 2011; 31: 307–13.Google Scholar
139Verstappen, SM, King, Y, Watson, KD, Symmons, DP, Hyrich, KL; BSRBR Control Centre Consortium, BSR Biologics Register. Concise report: anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologic Register. Ann Rheum Dis 2011; 70: 823–26.CrossRefGoogle Scholar
140Erkan, D, Locksin, MD. New treatments for antiphospholipid syndrome. Rheum Dis Clin N Am 2006; 32: 129–48.Google Scholar